Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens

Elaine A Sugarman, Narasimhan Nagan, Hui Zhu, Viatcheslav R Akmaev, Zhaoqing Zhou, Elizabeth M Rohlfs, Kerry Flynn, Brant C Hendrickson, Thomas Scholl, Deborah Alexa Sirko-Osadsa, Bernice A Allitto, Elaine A Sugarman, Narasimhan Nagan, Hui Zhu, Viatcheslav R Akmaev, Zhaoqing Zhou, Elizabeth M Rohlfs, Kerry Flynn, Brant C Hendrickson, Thomas Scholl, Deborah Alexa Sirko-Osadsa, Bernice A Allitto

Abstract

Spinal muscular atrophy (SMA) is a leading inherited cause of infant death with a reported incidence of ~1 in 10,000 live births and is second to cystic fibrosis as a common, life-shortening autosomal recessive disorder. The American College of Medical Genetics has recommended population carrier screening for SMA, regardless of race or ethnicity, to facilitate informed reproductive options, although other organizations have cited the need for additional large-scale studies before widespread implementation. We report our data from carrier testing (n = 72,453) and prenatal diagnosis (n = 121) for this condition. Our analysis of large-scale population carrier screening data (n = 68,471) demonstrates the technical feasibility of high throughput testing and provides mutation carrier and allele frequencies at a level of accuracy afforded by large data sets. In our United States pan-ethnic population, the calculated a priori carrier frequency of SMA is 1/54 with a detection rate of 91.2%, and the pan-ethnic disease incidence is calculated to be 1/11,000. Carrier frequency and detection rates provided for six major ethnic groups in the United States range from 1/47 and 94.8% in the Caucasian population to 1/72 and 70.5% in the African American population, respectively. This collective experience can be utilized to facilitate accurate pre- and post-test counseling in the settings of carrier screening and prenatal diagnosis for SMA.

References

    1. Miniño AM, Xu JQ, Kochanek KD. Deaths: preliminary data for 2008. National Center for Health Statistics: Hyattsville, MD; Natl Vital Stat Rep. 2010;59
    1. Ogino S, Leonard DG, Rennert H, Wilson RB. Spinal muscular atrophy genetic testing experience at an academic medical center. J Mol Diagn. 2002;4:53–58.
    1. Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy; clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518–523.
    1. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12:1015–1023.
    1. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA. 1999;96:6307–6311.
    1. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358–368.
    1. Prior TW, Krainer AR, Hua Y, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85:408–413.
    1. Mailman MD, Hemingway T, Darsey RL, et al. Hybrids monosomal for human chromosome 5 reveal the presence of a spinal muscular atrophy (SMA) carrier with two SMN1 copies on one chromosome. Hum Genet. 2001;108:109–115.
    1. McAndrew PE, Parsons DW, Simard LR, et al. Identification of spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997;60:1411–1422.
    1. Anhuf D, Eggermann T, Rudnik-Schoneborn S, Zerres K. Determination of SMN1 and SMN2 copy number using TaqMan technology. Hum Mutat. 2003;22:74–78.
    1. Su YN, Hung CC, Li H, et al. Quantitative analysis of SMN1 and SMN2 genes based on DHPLC: a highly efficient and reliable carrier-screening test. Hum Mutat. 2005;25:460–467.
    1. Scarciolla O, Stuppia L, DeAngelis MV, et al. Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification. Neurogenetics. 2006;7:269–276.
    1. Smith M, Calabro V, Chong B, Gardiner N, Cowie S, du Sart D. Population screening and cascade testing for carriers of SMA. Eur J Hum Genet. 2007;15:759–766.
    1. Yoon S, Lee CH, Lee KA. Determination of SMN1 and SMN2 copy numbers in Korean population using multiplex ligation dependent probe amplification. Korean J Lab Med. 2010;30:93–96.
    1. Ben-Shachar S, Orr-Urtreger A, Bardugo E, et al. Large-scale population screening for spinal muscular atrophy: Clinical implications. Genet Med. 2011;13:110–114.
    1. Sukenik-Halevy R, Pesso R, Garbian N, Magal N, Shohat M. Large scale population carrier screening for spinal muscular atrophy in Israel—effect of ethnicity on the false-negative rate. Genet Test Mol Biomarkers. 2010;14:319–324.
    1. Sheng-Yuan Z, Xiong F, Chen Y-J, et al. Molecular characterization of SMN copy number derived from carrier screening and from core families with SMA from a Chinese population. Eur J Hum Genet. 2010;18:978–984.
    1. Prior TW, Snyder PJ, Rink BD, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. 2010;152A:1608–1610.
    1. Prior TW. Carrier screening for spinal muscular atrophy. Genet Med. 2008;10:20–26.
    1. Gitlin J, Fishbeck K, Crawford TO, et al. Carrier testing for spinal muscular atrophy. Genet Med. 2010;10:621–622.
    1. Muralidharan K, Wilson R, Ogino S, Nagan N, Curtis C, Schrijver I. Population carrier screening for spinal muscular atrophy: A position statement of the Association for Molecular Pathology. J Mol Diag. 2011;13:3–6.
    1. ACOG Committee Opinion Spinal Muscular Atrophy. Obstet Gynecol. 2009;113:1194–1196.
    1. Wirth B, Herz M, Wetter A, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. 1999;64:1340–1356.
    1. Hedrickson BC, Donohoe C, Akmaev VR, et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet. 2009;46:641–644.
    1. Prior T, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet. 2004;130A:307–310.
    1. Bilardo CM, Timmerman E, Pajkrt E, van Maarle M. Increased nuchal translucency in euploid fetuses–what should we be telling parents. Prenat Diagn. 2010;30:93–102.
    1. Zadeh N, Hudgins L, Norton M. Nuchal translucency measurement in fetuses with spinal muscular atrophy. Prenat Diagn. 2011;31:327–330.

Source: PubMed

3
Abonneren